Acumen Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
ABOS$0.24+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(96,197) | $(65,175) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 46 | 49 |
| Stock-based compensation expense | 7,433 | 7,292 |
| Amortization of premiums and accretion of discounts on marketable securities, net | (919) | (4,599) |
| Change in fair value of embedded derivatives | 290 | (1,040) |
| Amortization of right-of-use asset | 93 | 85 |
| Realized gain on marketable securities | (17) | (97) |
| Noncash interest expense | 942 | 823 |
| Other noncash expense | — | 230 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,205 | (4,196) |
| Other long-term assets | 42 | 51 |
| Accounts payable | (4,966) | 963 |
| Accrued clinical trial expenses | (5,460) | 8,130 |
| Accrued expenses and other liabilities | 1,066 | (1,493) |
| Finance lease liability | — | (23) |
| Net cash used in operating activities | (96,442) | (59,000) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (38,056) | (155,631) |
| Proceeds from maturities and sales of marketable securities | 145,827 | 174,011 |
| Purchases of property and equipment | (88) | (16) |
| Net cash provided by investing activities | 107,683 | 18,364 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | — | 7,938 |
| Proceeds from exercise of stock options | 37 | — |
| Payment for financing lease | — | (739) |
| Payments for deferred offering costs | — | (230) |
| Repurchase of common shares to pay employee withholding taxes | (73) | (32) |
| Net cash provided by (used in) financing activities | (36) | 6,937 |
| Net change in cash and cash equivalents and restricted cash | 11,205 | (33,699) |
| Cash and cash equivalents and restricted cash at the beginning of the period | 35,859 | 67,119 |
| Cash and cash equivalents and restricted cash at the end of the period | $47,064 | $33,420 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for income taxes | $— | $— |
| Cash paid for interest | $2,203 | $2,235 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.